NCT06217094 - Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

September 30, 2029

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

NP-101 (3 g)

Subjects will be assigned to take 3 g of NP-101 orally once daily for 28 days pre Y-90 treatment.

DRUG

NP-101 (4.8 g)

Subjects will be assigned to take 4.8 g of NP-101 orally once daily for 28 days pre Y-90 treatment.

DRUG

NP-101 (6 g)

Subjects will be assigned to take 6 g of NP-101 orally once daily for 28 days pre Y-90 treatment.

Trial Locations (1)

University of Florida, Gainesville